Tag: Bispecific antibody
Phase 1 patient dosing of PT886 for advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas is initiated by Phanes Therapeutics.
First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb)…
Registration Form
This will close in 0 seconds
